NeOnc Technologies Holdings, Inc. (NTHI)
NASDAQ:NTHI
NTHI Stock Chart & Stats
$8.88
--
Market closed
$8.88
--
Day’s Range― - ―
52-Week Range$3.20 - $12.99
Previous CloseN/A
VolumeN/A
Average Volume (3M)103.40K
Market Cap
$127.84M
Enterprise Value$113.63M
Total Cash (Recent Filing)$58.73K
Total Debt (Recent Filing)$6.31M
Price to Earnings (P/E)―
Beta1.62
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding23,806,215
10 Day Avg. Volume39,098
30 Day Avg. Volume103,402
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)-9.07
Price to Sales (P/S)3973.02
P/FCF Ratio-7.62
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue2.84K
Enterprise Value/Gross Profit2.84K
Enterprise Value/Ebitda-1.74
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
NEO212 Phase 1 De-riskingEstablishing a Recommended Phase 2 Dose (610 mg) materially de-risks the NEO212 program: it enables a concrete Phase 2 design, regulatory engagement (Type B meeting planned), and clearer go/no-go decision points, improving the program's probability of clinical and regulatory progress.
Platform Breadth & IP ProtectionDemonstrated oral and intranasal CNS delivery plus a broad patent estate strengthens competitive differentiation. Multiple delivery modalities and patent coverage increase barriers to entry, expand development pathways, and support longer-term strategic options including partnerships or licensing.
Demonstrated Access To FinancingSuccessful private placements and an institutional PIPE anchor indicate the company can access capital to fund clinical programs. For a clinical-stage biotech, demonstrated financing capability is a durable strength that supports executing multi-year trials and regulatory milestones.
Bears Say
Minimal Revenue Vs Large LossesThe company's economics are characteristic of a pre-commercial biotech: negligible product revenue and outsized operating losses. This structural mismatch means value depends entirely on future clinical success and financing, raising long-term execution risk if programs stall.
Accelerating Cash BurnRapidly increasing cash outflows driven by R&D and G&A expansion materially shorten runway absent external funding. Persistent negative free cash flow forces repeated capital raises, which can dilute shareholders and constrain strategic flexibility over the medium term.
Weak Balance Sheet & Solvency RiskAn equity deficit, thin asset base, and rising debt indicate constrained financial flexibility and elevated solvency risk. This structural weakness reduces bargaining power with partners, increases reliance on dilutive financing, and could limit ability to scale programs if capital markets tighten.
NeOnc Technologies Holdings, Inc. News
NTHI FAQ
What was NeOnc Technologies Holdings, Inc.’s price range in the past 12 months?
NeOnc Technologies Holdings, Inc. lowest stock price was $3.20 and its highest was $12.99 in the past 12 months.
What is NeOnc Technologies Holdings, Inc.’s market cap?
NeOnc Technologies Holdings, Inc.’s market cap is $127.84M.
When is NeOnc Technologies Holdings, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were NeOnc Technologies Holdings, Inc.’s earnings last quarter?
Currently, no data Available
Is NeOnc Technologies Holdings, Inc. overvalued?
According to Wall Street analysts NeOnc Technologies Holdings, Inc.’s price is currently Overvalued.
Does NeOnc Technologies Holdings, Inc. pay dividends?
NeOnc Technologies Holdings, Inc. does not currently pay dividends.
What is NeOnc Technologies Holdings, Inc.’s EPS estimate?
NeOnc Technologies Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NeOnc Technologies Holdings, Inc. have?
NeOnc Technologies Holdings, Inc. has 23,806,215 shares outstanding.
What happened to NeOnc Technologies Holdings, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NeOnc Technologies Holdings, Inc.?
Currently, no hedge funds are holding shares in NTHI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NeOnc Technologies Holdings, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Bought Shares
Worth $153.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 8.4%
Last 30 Days ▼ 8.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
489.71%
Trailing 12-Months
Asset Growth
-17.37%
Trailing 12-Months
Company Description
NeOnc Technologies Holdings, Inc.
Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
Technical Analysis
Ownership Overview
55.39% Insiders
0.97% Mutual Funds
5.60% Other Institutional Investors
37.06% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---